Executives
-
Johnson Rady AExecutive Vice President -
Bourla AlbertChairman & CEO
-
Fonseca LidiaExecutive Vice President
-
Denton David MChief Financial Officer & EVP
-
Mcdermott MichaelExecutive Vice President
-
Dolsten MikaelPresident R&D
-
Susman SallyExecutive Vice President
-
Malik AamirExecutive Vice President
-
Sahni PayalExecutive Vice President
-
Lankler Douglas MExecutive Vice President
-
Damico Jennifer B.SVP & Controller
-
Baum AndrewExecutive Vice President
-
Boshoff ChristoffelExecutive Vice President
-
De Germay AlexandreExecutive Vice President
?
Damico Jennifer B.
SVP & Controller
Pfizer Inc.
US, New York [HQ]
CIK
1805617
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
85,820,000
Price per Share :
$26.49
Equivalence :
$2,273,371,800.00
Transaction History
-
S85,820,000 Shares After TransactionValue : $2,459,601,200.00Sold $1,477,136,400.00Transaction Date : 08/13/24
-
Footnotes
-
-
Footnotes:No footnote found.
-
A134,950,000 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/27/24
-
Footnotes
-
-
Footnotes:#1 The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.
-
M192,280,000 Shares After TransactionValue : $5,256,935,200.00$2,666,196,800.00Transaction Date : 02/23/24
-
Footnotes
-
-
Footnotes:#1 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.#2 Price is the closing price of Pfizer common stock on February 23, 2024.#3 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).#4 The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).#5 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.#6 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
-
F187,770,000 Shares After TransactionValue : $5,212,495,200.00$125,197,600.00Transaction Date : 02/23/24
-
Footnotes
-
-
Footnotes:#1 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.#2 Price is the closing price of Pfizer common stock on February 23, 2024.#3 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).#4 The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).#5 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.#6 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
-
F180,030,000 Shares After TransactionValue : $4,997,632,800.00$214,862,400.00Transaction Date : 02/23/24
-
Footnotes
-
-
Footnotes:#1 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.#2 Price is the closing price of Pfizer common stock on February 23, 2024.#3 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).#4 The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).#5 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.#6 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).